Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

Annals of Neurology

Volumn 40, Issue 6, 1996, Pages 873-884

  Frey, Kirk A ^a,b,c   Koeppe, Robert A ^a   Kilbourn, Michael R ^a   Vander Borght, Thierry M ^a   Albin, Roger L ^a   Gilman, Sid ^a   Kuhl, David E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; CARBON 11; CARRIER PROTEIN; DIHYDROTETRABENAZINE; LEVODOPA; MONOAMINE; SELEGILINE;

ADULT; AGED; AGING; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BLOOD BRAIN BARRIER; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONOAMINERGIC NERVE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PUTAMEN; RAT; SYNAPSE VESICLE;

ADULT; AGED; AGING; ANIMALS; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEUROPEPTIDES; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; RATS; TETRABENAZINE; TOMOGRAPHY, EMISSION-COMPUTED; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0030511826     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400609     Document Type: Article

References (66)

1. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966;18:925-965
2. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880
3. Daniel SE. The neuropathology and neurochemistry of multiple system atrophy. In: Bannister R, Mathias CJ, eds. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. 3rd ed. Oxford: Oxford University Press, 1992:564-585
4. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brainstem, basal ganglia, and cerebellum, with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-358
5. Tanner CM, Langston JW. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 1990;40(suppl 3):17-30
6. Rajput AH. Environmental causation of Parkinson's disease. Arch Neurol 1993;50:651-652
7. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250
8. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812
9. Sian J, Dexter DT, Lees AJ, et al. Alrerations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355
10. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in Parkinson's disease. N Engl J Med 1993;328:176-183
11. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723
12. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983;305:137-138
13. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298
14. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431
15. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-1181
16. Vander Borght TM, Kilbourn MR, Koeppe RA, et al. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med 1995;36:2252-2260
17. Vander Borght T, Kilbourn M, Desmond T, et al. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1996;294:577-583
18. Naudon L, Leroux-Nicollet I, Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter. Neurosci Lett 1994;173:1-4
19. 3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995;68:955-962
20. Gilman S, Frey KA, Koeppe RA, et al. Decreased striatal monoaminergic terminals in OPCA and MSA demonstrated with PET. Ann Neurol 1996 (In press)
21. Hoehn MM, Yahr, MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442
22. 11C]TBZ, a vesicular monoamine uptake inhibitor, for PET imaging studies. Appl Radiat Isot 1993;44:673-676
23. Kilbourn M, Lee L, Vander Borght T, et al. Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 1995;278:249-252
24. 11C]scopolamine and positron emission tomography. J Cereb Blood Flow Metab 1992;12:147-154
25. Frey KA, Holthoff VA, Koeppe RA, et al. Parametric in vivo imaging of benzodiazepine receptor distribution in human brain. Ann Neurol 1991;30:663-672
26. 11C]Tropanyl benzilaTe-binding to muscarinic cholinergic receptors: methodology and kinetic modeling alternatives. J Cereb Blood Flow Metab 1994;14:85-99
27. 3H]Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 1988;50:1131-1136
28. Pearson SJ, Reynolds GP. Depletion of monoamine neurotransmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 1988;27:717-719
29. Erickson JD, Eiden LE. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J Neurochem 1993;61:2314-2317
30. Kish SJ, Robitallle Y, el-Awar M, et al. Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 1992;42:1573-1577
31. Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain monoamine transporters. Nucl Med Biol 1996 (In press)
32. Gjedde A, Reith J, Dyve S, et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad SCi USA 1991;88: 2721-2725
33. Hadjiconstantinou M, Wemlinger TA, Sylvia CP, et al. Aromatic l-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J Neurochem 1993;60: 2175-2180
34. Young EA, Neff NH, Hadjiconstantinou M. Evidence for cyclic AMP-mediated increase of aromatic L-amino acid decarboxylase activity in the striatum and midbrain. J Neurochem 1993;60:2331-2333
35. Zhu M-Y, Jucrio AV, Paterson IA, Boulton AA. Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. Eur J Pharmacol 1993; 238:157-164
36. Cumming P, Kuwabara H, Ase A, Gjedde A. Regulation of DOPA decarboxylase activity in brain of living rat. J Neurochem 1995;65:1381-1390
37. Weiner HL, Hashim A, Lajtha A, Sershen H. Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol 1989;163:191-194
38. Ikegami H, Prasad C. Neuropeptide-dopamine interactions. V. Cyclo(his-pro) regulation of striatal dopamine transporter complex. Peptides 1990;11:145-148
39. Meiergerd SM, Hooks SM, Schenk JO. The striatal transporter for dopamine in the rat may be kinetically up-regulated following 3 weeks of withdrawal from cocaine self-administration. J Neurochem 1994;63:1277-1281
40. 3H-GBR 12,935 are differentially regulated by chronic cocaine self-administration. J Neurosci 1994;14:2966-2979
41. 11C]tetrabenazine and positron emission tomography. J Neurochem 1993;60:2315-2318
42. Kilbourn MR, Lee LC, Jewett DM, et al. In vitro and in vivo binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. J Cereb Blood Flow Metab 1995; 15(suppl 1):S650 (Abstract)
43. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977;34:33-35
44. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301
45. Scherman D, Desnos G, Darchen F, et al. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1989;26:551-557
46. Zelnik N, Angel I, Paul SM, Kleinman JE. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol 1986;126:175-176
47. De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 1990;27:157-161
48. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994;36:237-239
49. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989;26:535-542
50. Cordes M, Snow BJ, Cooper S, et al. Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren. Ann Neurol 1994;36:667-670
51. Sawle GV, Colebatch JG, Shah A, et al. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990;28:799-804
52. 18F-DOPA uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993;13:881-888
53. Kish SJ, Zhong XH, Hornykiewicz O, Haycock JW. Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging; disparity between portmortem and positron emission tomography studies? Ann Neurol 1995;38:260-264
54. Lehéricy S, Brandel J-P, Hirsch EC, et al. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res 1994;659:1-9
55. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455
56. Niznik HB, Fogel EF, Fassos F, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991:56:192-198
57. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sires associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991;9:43-49
58. 3H]mazindol. Neuroscience 1992;49:317-327
59. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598
60. Sawle GV, Playford ED, Burn DJ, et al. Sepatating Parkinson's disease from normality. Arch Neurol 1994;51:237-243
61. Hefti F, Melamed E, Wurtman RJ. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 1980;195:123-137
62. Zhong X-H, Haycock JW, Shannak K, et al. Striatal dihydrophenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy. Mov Disord 1995;10:10-17
63. Gjedde A, Léger GC, Gumming P, et al. Striatal L-DOPA decarboxylase activity in Patkinson's disease in vivo: Implications for the regulation of dopamine synthesis. J Neurochem 1993;61:1538-1541
64. Marquardt DW. An algorithm for least squares estimation of nonlinear parameters. J Soc Indust Appl Math 1963;11:431-441
65. Alpert NM, Eriksson L, Chang JY, et al. Strategy for the measurement of regional cerebral blood flow using short-lived tracers and emission tomography. J Cereb Blood Flow Metab 1984;4:28-34
66. 11C]dihydrotetrabenazine by dynamic PET: measurement of the vesicular monoamine transporter. J Cereb Blood Flow Metab 1996 (In press)